Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...

Browse through the latest SEC filings such as 10-Ks, 10-Qs, and other essential financial disclosures. Stay compliant and informed with detailed reports on company performance, risks, and regulatory ...